Prioritisation of head, neck, and respiratory outcomes in mucopolysaccharidosis type II: lessons from a rare disease consensus exercise and comparison of parental and clinical priorities
Authors:
Open Access
- 26 February 2025
- journal article
- research article
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 20 (1) , 1-15
Abstract
Background: The mucopolysaccharidoses are a group of rare, inherited metabolic disorders. MPS II is a X-linked recessive disease, also known as Hunter syndrome. Clinical manifestations include upper and lower respiratory tract, and head and neck pathologies influencing quality of life, morbidity, and mortality. Medical and surgical intervention outcomes for MPS are reported inconsistently, creating a challenge when synthesising and contrasting evidence. This study set out to address the inconsistency in outcome measurement in this field. International recommendations for developing a core outcome set were adopted. Available data from qualitative studies and outcomes from a modified e-Delphi surveys were used to develop a list of candidate outcomes for consideration. Three consensus meetings with patients diagnosed with MPS II alongside their parents/carers were ran to help finalise a list of outcome domains. Results: Survival, airway obstruction, and quality of life were outcomes identified as important to always measure in all MPS II clinical trials and/or in clinical practice. Other outcomes for younger children included swallowing difficulties, cognitive development, ability to participate in education, and communication. The adolescent group included safety of chewing and swallowing, complications of anaesthesia, sleep quality and apnoea, nasal problems, and chronic otitis media. The adult group identified sleep apnoea, and hearing, as additional outcomes to measure. Conclusions: A novel methodology for determining a core outcome set in rare diseases has been recommended. Both functional and quality of life outcomes were identified by the three age groups of individuals and/or their parents. Adoption of these sets of outcomes in future clinical trials and/or clinical practice will enable comparison of outcomes reported.Keywords
Funding Information
- Shire International GmbH (IIR-GBR-000133)
This publication has 37 references indexed in Scilit:
- Management of otolaryngological manifestations in mucopolysaccharidoses: our experience2013
- Driving up the Quality and Relevance of Research Through the Use of Agreed Core OutcomesJournal of Health Services Research & Policy, 2012
- Overview of the mucopolysaccharidosesRheumatology, 2011
- Mortality and cause of death in mucopolysaccharidosis type II—a historical review based on data from the Hunter Outcome Survey (HOS)Journal of Inherited Metabolic Disease, 2009
- Avoidable waste in the production and reporting of research evidenceThe Lancet, 2009
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ, 2008
- Diagnosis and management of respiratory involvement in Hunter syndromeActa Paediatrica, 2008
- Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapyEuropean Journal of Pediatrics, 2007
- Otorhinolaryngological manifestations of the mucopolysaccharidosesInternational Journal of Pediatric Otorhinolaryngology, 2005
- A critical review of the Delphi technique as a research methodology for nursingInternational Journal of Nursing Studies, 2001